Please login to post a response.

• important news on Avastin
• Posted: 2007-10-30 12:17:54 By dan r
• Dear Friends,
  
  Genentech senior executives recently met with American Academy of Ophthalmology (AAO) and American Society of Retina Specialists (ASRS) leadership to discuss the company's decision to stop supplying Avastin directly to compounding pharmacies.
  
  I'm pleased to announce that two major agreements were reached:
  
  1) January 1, 2008, rather than November 30, 2007, is now the date on which Genentech will discontinue the supply of Avastin to compounding pharmacies. This allows affected physicians sufficient time to develop and implement transition plans.
  
  2) Genentech will reinstate its supply of Avastin to compounding pharmacies if the FDA gives the company legal and regulatory authorization to do so.
  
  For more details about the delivery process of Avastin and the recent agreements, see Genentech's open letter to the community at:
  
  http://www.gene.com/gene/features/avastin/open-letter.jsp
  
  MD Support recognizes that Genentech has obligations to its investors, but also that the company is concerned for our welfare and maintains the highest integrity in its commitment to us. We appreciate not only the work they have done to bring Lucentis to market, but their willingness to continue in collaboration with the professional community and to keep us all informed.
  
  Best regards,
  
  Dan Roberts, Director
  MD Support
  www.mdsupport.org